Compare Deutsche Bank AG (DB) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deutsche Bank AG vs Sanofi SA — how do they compare? Deutsche Bank AG trades at $33.61 (market cap $62.42B), while Sanofi SA trades at $40.1 (market cap $96.81B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (6.02%). Which is the better fit depends on your goals — on Pluang, investors hold Deutsche Bank AG for 80 Days and Sanofi SA for 94 Days on average.
| DB | SNY | |
|---|---|---|
Market Cap | $62.42B | $96.81B |
Volume | 2,918,760 | 2,081,815 |
Sector | Financials | Health |
52-Week High | $41.56 | $52.34 |
52-Week Low | $28.37 | $39.51 |
Typical Hold Time | 80 Days | 94 Days |
Enterprise Value | $77.06B | $116.20B |
Dividend Yield | 3.46% | 6.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deutsche Bank (DB) trades at $33.55, down 4.5% amid concerns over Q3 investment banking revenue. The stock shows attractive valuation with P/E of 9.1 and P/B of 0.71, while fundamentals improved with 2025 net income reaching $6.93B. Technical indicators signal bearish momentum with price near support at $33. Recent news highlights management's focus on 2028 targets and wealth management growth.
The outlook remains mixed - strong fundamentals and undervaluation present opportunity, but near-term headwinds in investment banking and bearish technicals suggest caution. Key risks include revenue volatility and European economic pressures, while analyst consensus leans neutral with 57.6% hold ratings.
SNY trades at $40.2, up 1.62% on the day, with a bearish technical signal from moving averages but a neutral oscillator stance. The company reported revenue of $46.72B in 2025 with a net income margin of 16.72%, and it has beaten EPS estimates for the last three quarters. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling strong pipeline development.
The outlook is mixed; analyst consensus leans hold (51.86%) with a buy rating at 44.44%, reflecting optimism on new drug launches but caution over future profit margin compression projected for 2026. Key risks include execution of the expanded Regeneron partnership and managing debt levels amid investing cash flow volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
